John W. Eikelboom
Population Health Research Institute
Publications 767
Managing severe valvular heart disease with mechanical valve replacement necessitates lifelong anticoagulation with a vitamin K antagonist. Optimal anticoagulation intensity for patients with mecha...
#1Stefan M. NidorfH-Index: 7
#2Aernoud T.L. Fiolet (UU: Utrecht University)H-Index: 2
Last.Peter L. Thompson (SCGH: Sir Charles Gairdner Hospital)H-Index: 38
view all 11 authors...
Abstract Background Because patients with stable coronary artery disease are at continued risk of major atherosclerotic events despite effective secondary prevention strategies, there is a need to continue to develop additional safe, effective and well-tolerated therapies for secondary prevention of cardiovascular disease. Rationale and Design The LoDoCo (Low Dose Colchicine) pilot trial showed that the anti-inflammatory drug colchicine 0.5 mg once daily appears safe and effective for secondary ...
Background and Purpose— Diabetes mellitus (DM) and non-DM patients without coronary artery disease (CAD) have a similar low risk of myocardial infarction after coronary angiography. The risk of isc...
#1Robert C. Welsh (U of A: University of Alberta)H-Index: 38
#2Eric D. Peterson (Duke University)H-Index: 149
Last.John W. Eikelboom (Population Health Research Institute)H-Index: 93
view all 6 authors...
Abstract For four decades, anti-thrombotic therapy with aspirin has been a cornerstone of secondary prevention for patients with chronic atherosclerotic cardiovascular disease (ASCVD). Unfortunately, despite the use of evidence-based therapies, patients with ASCVD continue to have recurrent major adverse cardiovascular (CV) events including death, myocardial infarction and stroke -- at a rate of approximately 2–4% per year. To combat this continuing risk, several recent trials have evaluated the...
Abstract The achievements with antithrombotic therapy over the past 50 years have been monumental and the disappointments relatively few. In this review, we will discuss, chronologically, the major developments of the two recognized classes of antithrombotics - anticoagulants and antiplatelet agents.
#1John W. Eikelboom (Population Health Research Institute)H-Index: 93
#2Stuart J. Connolly (Population Health Research Institute)H-Index: 56
Last.Salim Yusuf Mb Bs DPhil Frcpc (Population Health Research Institute)H-Index: 214
view all 22 authors...
Background: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the first manifestation of underlying cancer. Methods: We examined new cancers diagnosed in relation ...
1 CitationsSource